Fanny Pommeret
A5079807284- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- COVID-19 Impact on Reproduction
- Sarcoma Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- Multiple and Secondary Primary Cancers
- Frailty in Older Adults
- Economic and Financial Impacts of Cancer
- Immune Cell Function and Interaction
- Breast Lesions and Carcinomas
- Hepatitis C virus research
- Nutrition and Health in Aging
- S100 Proteins and Annexins
- Endometrial and Cervical Cancer Treatments
- Renal Diseases and Glomerulopathies
- Cancer Diagnosis and Treatment
- Cancer and Skin Lesions
- COVID-19 and Mental Health
- Safe Handling of Antineoplastic Drugs
- Kawasaki Disease and Coronary Complications
Institut Gustave Roussy
2017-2024
Université Paris-Saclay
2019-2024
Arcagy Gineco
2022
Institut Bergonié
2019-2021
Collaborative Group (United States)
2020
Inserm
2019
Université Paris-Sud
2019
Université de Bordeaux
2016
Abstract The circulating metabolome provides a snapshot of the physiological state organism responding to pathogenic challenges. Here we report alterations in plasma reflecting clinical presentation COVID-19 patients with mild (ambulatory) diseases, moderate disease (radiologically confirmed pneumonitis, hospitalization and oxygen therapy), critical (in intensive care). This analysis revealed major disease- stage-associated shifts metabolome, meaning that at least 77 metabolites including...
Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes due underlying malignancy and treatment-induced immunosuppression. Of the first 178 patients managed for Gustave Roussy Cancer Centre, 125 (70.2%) were hospitalized, 47 (26.4%) developed clinical worsening 31 (17.4%) died. An age over 70 years, smoking status, metastatic disease, cytotoxic chemotherapy an Eastern Cooperative Oncology Group score ≥2 last visit strongest determinants death. In multivariable...
Whether the severity and mortality of COVID-19 in patients with cancer have improved terms disease management capacity is yet to be defined.To test whether from among during course pandemic.OnCovid a European registry that collects data on consecutive solid or hematologic COVID-19. This multicenter case series study included real-world 35 institutions across 6 countries (UK, Italy, Spain, France, Belgium, Germany). update diagnosed between February 27, 2020, February, 14, 2021. Inclusion...
Objective To evaluate the efficacy of covid-19 convalescent plasma to treat patients admitted hospital for moderate disease with or without underlying immunodeficiency (CORIPLASM trial). Design Open label, randomised clinical trial. Setting CORIMUNO-19 cohort (publicly supported platform open controlled trials immune modulatory drugs in severe disease) based on 19 university and general hospitals across France, from 16 April 2020 21 2021. Participants 120 adults (n=60 group, n=60 usual care...
Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during therapies remain elusive. When comparing nasopharyngeal swabs from and noncancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 (58% cancer), we found that malignant favors magnitude duration viral RNA shedding concomitant prolonged serum elevations type 1 IFN...
We explored, within the EORTC10994 study, outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) progesterone (PR) negative. also assessed concordance between IHC gene expression arrays (GEA) in identification of MA cancers. Centrally biopsies AR, ER, PR, HER2 Ki67 by were classified into six subtypes: MA, triple-negative (TN) basal-like, luminal A, B negative, positive "other". The two main...
Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post-COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated the development COVID-19 sequelae.
Abstract Background: The SARS-CoV-2 outbreak in Paris’ region significantly affected Gustave Roussy cancer center. Here, we report the experience during outbreak. This has led to a rapid reorganization of patients’ (pts) management, with two concurrent objectives. First, protect pts, who may more severe form disease, from being infected by SARS-CoV-2. Second, pts losing chance receive optimal, if not standard, care. Methods: Cancer suspected infection were admitted at starting March, 12th....
Severe COVID-19 is associated with a high circulating level of calprotectin, the S100A8/S100A9 alarmin heterodimer. Baseline calprotectin amount measured in peripheral blood at diagnosis correlates disease severity. The optimal use this biomarker along course remains to be delineated.We focused on patients WHO-defined moderate requiring hospitalization medical ward. We collected plasma and serum from three independent cohorts (N = 626 patients) admission. performed longitudinal measures 457...
Abstract Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized polarity and specificity memory T cells directed SARS-CoV-2 viral lysates peptides determine correlates with spontaneous, virus-elicited, or vaccine-induced protection COVID-19 in disease-free cancer-bearing individuals. A disbalance between type 1 2 cytokine release was...
Abstract Objectives Efficacy of convalescent plasma in COVID-19 pneumonia (CPP) is uncertain, especially immunocompromised patients. CORIMUNO-CORIPLASM an open-label, Bayesian randomised clinical trial embedded the CORIMUNO trials platform that evaluated efficacy CCP patients with moderate COVID-19. Setting 19 university and general hospitals across France. Participants Adult hospitalized a positive SARS-CoV2 test, duration symptoms < 9 days WHO score severity 4 or 5 who signed written...
As management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects severity in patients with cancer. In a joint analysis of ICI recipients from OnCovid (NCT04393974) European Society for Medical Oncology (ESMO) CoCARE registries, we assessed mortality SARS-CoV-2 vaccinated unvaccinated cancer explored immune-related adverse events (irAEs) influenced outcome COVID-19. The study population consisted 240...
Abstract Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during therapies remain elusive. When comparing nasopharyngeal swabs from and non-cancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 (58% cancer, 89% COVID-19 + ), we found that malignant favors magnitude duration viral RNA shedding concomitant prolonged serum...
Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest population. Breast cancer seem to have better prognosis when infected by SARS-CoV-2 other patients. Methods: We report a subanalysis OnCovid study providing more detailed information in breast Results: included 495 with infection. Mean age was 62.6 years; 31.5% presented one comorbidity. The most frequent subtype luminal-like ( n = 245, 49.5%) 177 (35.8%) had metastatic disease. A total 332...